MedTrace Logo

Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke

NCT06857487 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-12-01

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Qingre Huatan Formula

Qingre Huatan Formula, granules, 1 bag each time, twice a day, orally, continue for 10 days.

DRUG

Qingre Huatan Formula placebo

Qingre Huatan Formula placebo, granules, 1 bag each time, twice a day, orally, continue for 10 days.

OTHER

Guidelines-based standard care

Guidelines-based standard care for acute ischemic stroke

Sponsors & Collaborators

  • Dongzhimen Hospital, Beijing

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-13
Primary Completion
2026-10-24
Completion
2026-10-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06857487 on ClinicalTrials.gov